Lunit Appoints Seasoned Healthcare IT Executive as Chief Business Officer
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced the appointment of Teri Thomas as Chief Business Officer (CBO) of its Cancer Screening Group. Thomas, who will commence her new role on July 1, brings over 25 years of executive management experience in healthcare IT to her new position.
A Proven Track Record in Healthcare IT
Thomas’s impressive career includes a notable 20-year tenure at Epic, a global healthcare systems provider, where she played a pivotal role in the company’s remarkable growth from under 100 employees to over 10,000. Her expertise spans strategy, operations, global sales, marketing leadership, with a deep understanding of the US healthcare market. As a registered nurse with a Master of Science degree, Thomas offers a unique perspective on the intersection of IT, clinician workflow, and patient experience.
The intersection of healthcare IT and patient experience is crucial in cancer screening.
Thomas’s appointment as CBO is a strategic move by Lunit to expand its business in the US and EMEA markets. With her extensive experience in healthcare IT and proven track record of driving growth, Thomas is well-equipped to lead the Cancer Screening Group and make a significant impact on early cancer detection.
A New Era for Lunit and Volpara
The appointment of Thomas comes at a time of strong financial performance for Volpara, which recently reported a robust 30% year-over-year increase in revenue for the first half of the fiscal year. Volpara also achieved a net cash flow positive position, marking a significant turnaround from a net outflow during the same period last year.
Cancer screening technology is advancing rapidly, with AI playing a crucial role.
The merger between Lunit and Volpara, as reported in an ITN Lunit Volpara news update, has positioned the unified company at the forefront of AI-driven cancer detection and personalized cancer care solutions. With Thomas at the helm of the Cancer Screening Group, Lunit is poised to make a significant impact in the healthcare industry.
A Bright Future for Cancer Screening
Thomas expressed her enthusiasm for the new role, stating, “I’m excited to join Lunit and lead the Cancer Screening Group. Our combined expertise in AI and breast health presents a unique, holistic AI suite to make a significant impact on early cancer detection and ultimately save lives.”
AI is revolutionizing cancer screening, enabling early detection and personalized care.
With Thomas’s appointment, Lunit is set to continue its mission to harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. As the company continues to expand its reach globally, one thing is clear – the future of cancer screening has never looked brighter.
Brandon Suh, Lunit CEO, welcomed Thomas to the leadership team, saying, “Her extensive experience in healthcare IT and proven track record of driving growth will be invaluable as we continue to expand the reach of our cancer screening technologies globally.”
 Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics.
